| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Maurie Markman | |
| P2860 | cites work | Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route | Q71228870 |
| Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy | Q71393681 | ||
| The route of absorption of intraperitoneally administered compounds | Q71828308 | ||
| Intraperitoneal cisplatin with systemic thiosulfate protection | Q71842628 | ||
| Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer | Q72874700 | ||
| Use of nitrogen mustard in treatment of serous effusions of neoplastic origin | Q73851004 | ||
| Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer | Q74506938 | ||
| A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment | Q74506982 | ||
| INTRACAVITARY 5-FLUOROURACIL IN MALIGNANT EFFUSIONS | Q78483501 | ||
| Critical thinking: an essential role in both the conduct and interpretation of gynecologic cancer clinical research | Q79831442 | ||
| A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers | Q80790079 | ||
| Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses | Q33269777 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer | Q33378686 | ||
| Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy | Q33397623 | ||
| Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. | Q33476440 | ||
| A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma | Q33490349 | ||
| Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 | ||
| Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer | Q34582674 | ||
| Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin | Q34604181 | ||
| High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up | Q34743376 | ||
| Intraperitoneal antineoplastic drug delivery: rationale and results | Q35121705 | ||
| Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer | Q36079934 | ||
| Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment | Q36388620 | ||
| Can carboplatin replace cisplatin for intraperitoneal use? | Q37108668 | ||
| Distant metastases in epithelial ovarian carcinoma | Q39778247 | ||
| Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest | Q40650351 | ||
| Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread | Q44051249 | ||
| Peritoneal electrolyte absorption: analysis of portal, systemic venous, and lymphatic transport | Q44173666 | ||
| cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. | Q45999456 | ||
| Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy | Q46212194 | ||
| Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group | Q46355629 | ||
| Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal | Q46646219 | ||
| First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up | Q47621107 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer | Q50512108 | ||
| A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. | Q51914485 | ||
| In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. | Q52265784 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. | Q53298171 | ||
| Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. | Q54595030 | ||
| Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. | Q55488965 | ||
| Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy | Q67919758 | ||
| Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer | Q67975858 | ||
| Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer | Q68034499 | ||
| Pharmacokinetics of carboplatin after intraperitoneal administration | Q68126770 | ||
| Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer | Q68694042 | ||
| Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy | Q69609509 | ||
| Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat | Q70263866 | ||
| Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer | Q70424229 | ||
| Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro | Q70866962 | ||
| P433 | issue | 1 | |
| P921 | main subject | ovarian cancer | Q172341 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 161-168 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin | |
| P478 | volume | 5 |
| Q51321999 | Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes. |
| Q36790826 | Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. |
| Q39739012 | Reducing excessive toxicity in ovarian cancer treatment: a personalized approach |
| Q34676773 | Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer |
| Q33685268 | Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells |
| Q36321710 | Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology |
Search more.